OSSIO
- Industry
- Orthopedic Medical Devices
- Founded Year
- 2014
- Headquarters
- Woburn, Massachusetts, USA
- Employee Count
- 143
Key People
- Brian Verrier - Chief Executive Officer
- Orahn Preiss-Bloom - Founder & Chief Innovation Officer
- Brennan Marilla - Chief Commercial and Operating Officer
- Moshe Shneor - Chief Financial Officer
- Taly Lindner, Ph.D. - Vice President, Scientific & Regulatory Affairs
- Ronit Merchav-Feuermann, DVM - Vice President, Clinical & Medical Affairs
- Dani Bar-Lev - Vice President, Quality Assurance
- Gregory C. Berlet, MD, FRCS(C), FAOA - Chief Medical Officer
- Jonathan Bar - Vice President, Operations
- Tal Zeevi - Vice President, R&D
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful backgrounds in the MedTech industry.
The presence of multiple successful MedTech entrepreneurs in the leadership team enhances the company's strategic direction and operational execution.
- Clinical Need
-
Aspect: Very Strong
Summary: OSSIO addresses a significant clinical need by providing bio-integrative implants that eliminate the need for metal hardware removal.
By offering implants that integrate with natural bone and eliminate permanent hardware, OSSIO addresses a major pain point in orthopedic surgeries.
- Competition
-
Aspect: First mover
Summary: OSSIO is pioneering the bio-integrative implant space, facing limited direct competition.
While leading the market offers advantages, it also involves educating the market and overcoming initial adoption barriers.
- Technical Challenge
-
Aspect: Predictable
Summary: The technology is based on established principles, making technical challenges manageable.
The use of bio-integrative materials in implants is well-understood, reducing the likelihood of unforeseen technical issues.
- Patent
-
Aspect: Very Strong
Summary: OSSIO holds robust patents protecting its bio-integrative implant technology.
Comprehensive patents safeguard the technology, preventing competitors from easily replicating the innovation.
- Financing
-
Aspect: Well-funded
Summary: OSSIO has secured substantial funding from reputable investors, supporting its growth and development.
The company's ability to attract significant investment indicates confidence in its potential, but ongoing funding will be necessary to maintain momentum.
- Regulatory
-
Aspect: 510k/PMA
Summary: OSSIO's products have received necessary regulatory approvals, facilitating market entry.
Achieving 510(k) clearance or PMA approval allows the company to market its products, but ongoing regulatory vigilance is required to ensure continued compliance.
Opportunity Rollup
- Odds of Success
- 3.6
- Peak Market Share
- 4.35
- Segment CAGR
- 3.0%
- Market Segment
- Orthopedic Devices
- Market Sub Segment
- Orthopedic Fixation Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.22 |
| 2 | 0.65 |
| 3 | 1.52 |
| 4 | 3.05 |
| 5 | 4.35 |
Key Takeaway
OSSIO's innovative bio-integrative implant technology positions it well in the orthopedic fixation market, with strong leadership and substantial funding supporting its growth trajectory.